A regulação das patentes farmacêuticas no Brasil: entre saúde pública, política e direito

• Autor(a) principal: Guimarães, Eduardo Ribas de Biase
• Data de Publicação: 2013
• Tipo de documento: Tese
• Idioma: por
• Título da fonte: Biblioteca Digital de Teses e Dissertações da UERJ
• Texto Completo: http://www.bdtd.uerj.br/handle/1/4639
• topic: Intellectual property; Pharmaceutical patents; Access to health; Anvisa´s prior consent; Sociology; Health Services Accessibility; Propriedade intelectual; Patentes farmacêuticas; Acesso à saúde; Anuência prévia; Sociologia; Medicamentos - Patentes; Acesso aos Serviços de Saúde; Aprovação de medicamentos; CNPQ::CIENCIAS DA SAUDE::SAUDE COLETIVA

The general aim of the thesis is to improve the reflection on the regulation and the quality of examination of pharmaceutical patents in Brazil, in the context of implementation of legal provisions known as TRIPS-Plus around the world. For this, we discuss the legal and political mechanisms to protect health related to intellectual property rights. It examines specifically from a sociological point of view the experiences of the prior consent for patent applications involving pharmaceutical products and processes of the National Health Surveillance Agency (ANVISA) and the use of the patent opposition mechanism (subsídio ao exame técnico). In terms of methodology, it considers the actions of the Brazilian Government from 1996 to 2012, the proposals to change the Brazilian Industrial Property Law and the controversies linked to some types of patent claims, such as polymorphs, selection patents and second medical use. The research techniques also include the analysis of press materials, texts of laws, decrees and documents related to medicines and intellectual property, as well as patent applications and judgments. Interviews with managers, patent examiners, lawyers and members of NGOs were also conducted. The conclusions indicate that the regulatory practices related to the health sector can not be reduced to a simple body of formal rules present in this area, but rather understood as assemblages between actors, different types of knowledge and intervention tools. The regulation of intellectual property rights related to pharmaceutical products and processes in Brazil is linked to a process in which there is a dispute around the different projects and worldviews of groups with more or less power to drive this process. The devices of the prior consent and the patent opposition appear as regulatory elements of the intellectual property rights of drugs and of impact on the quality of examination of pharmaceutical patents, contributing to the consideration of public health concerns along the granting of these patents.